Inhibition of HSP90 molecular chaperones: Moving into the clinic

The Lancet Oncology

Volumn 14, Issue 9, 2013, Pages

  Garcia Carbonero, Rocio ^a,b   Carnero, Amancio ^a   Paz Ares, Luis ^a,b  

^a Instituto de Biomedicina de Sevilla   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALVESPIMYCIN; AT 13387; BORTEZOMIB; CISPLATIN; CRIZOTINIB; CYTARABINE; DOCETAXEL; GANETESPIB; GELDANAMYCIN; GEMCITABINE; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; IPI 493; IRINOTECAN; KW 2478; LUMINESPIB; NVP HSP990; PACLITAXEL; PLACEBO; PROTEASOME; PURINE DERIVATIVE; RESORCINOL DERIVATIVE; RETASPIMYCIN; SORAFENIB; SUNITINIB; TANESPIMYCIN; TRASTUZUMAB; UBIQUITIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BREAST CANCER; CANCER THERAPY; CARCINOGENESIS; CARDIOPULMONARY ARREST; CARDIOTOXICITY; CELL VIABILITY; DIARRHEA; DOWN REGULATION; DRUG BINDING; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE DISEASE; EYE TOXICITY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; HUMAN; INFUSION RELATED REACTION; INJECTION SITE IRRITATION; KIDNEY CANCER; KIDNEY FAILURE; LIVER FAILURE; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MELANOMA; METABOLIC ACIDOSIS; MULTIPLE MYELOMA; MYELOMA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SOLID TUMOR; VISUAL DISORDER; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR CHAPERONES; NEOPLASMS;

EID: 84880787644     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70169-4     Document Type: Review

References (91)

1. Macario AJ, Conway de Macario E Sick chaperones, cellular stress, and disease. N Engl J Med 2005, 353:1489-1501.
2. Powers MV, Workman P Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett 2007, 581:3758-3769.
3. Whitesell L, Lindquist SL HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005, 5:761-772.
4. Neckers L, Workman P Hsp90 molecular chaperone inhibitors: are we there yet?. Clin Cancer Res 2012, 18:64-76.
5. Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K, Giles FJ Targeting HSP90 for cancer therapy. Br J Cancer 2009, 100:1523-1529.
6. Münster PN, Marchion DC, Basso AD, Rosen N Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway. Cancer Res 2002, 62:3132-3137.
7. Shimamura T, Li D, Ji H, et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res 2008, 68:5827-5838.
8. Fumo G, Akin C, Metcalfe DD, Neckers L 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 2004, 103:1078-1084.
9. Grbovic OM, Basso AD, Sawai A, et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci USA 2006, 103:57-62.
10. Bonvini P, Dalla Rosa H, Vignes N, Rosolen A Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein. Cancer Res 2004, 64:3256-3264.
11. Whitesell L, Sutphin PD, Pulcini EJ, Martinez JD, Cook PH The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol 1998, 18:1517-1524.
12. Park Y, Kubo A, Komiya T, et al. Low-penetrant RB allele in small-cell cancer shows geldanamycin instability and discordant expression with mutant ras. Cell Cycle 2008, 7:2384-2391.
13. Dias S, Shmelkov SV, Lam G, Rafii S VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 2002, 99:2532-2540.
14. Forsythe HL, Jarvis JL, Turner JW, Elmore LW, Holt SE Stable association of hsp90 and p23, but not hsp70, with active human telomerase. J Biol Chem 2001, 276:15571-15574.
15. Connell P, Ballinger CA, Jiang J, et al. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol 2001, 3:93-96.
16. Lotz GP, Lin H, Harst A, Obermann WM Aha1 binds to the middle domain of Hsp90, contributes to client protein activation, and stimulates the ATPase activity of the molecular chaperone. J Biol Chem 2003, 278:17228-17235.
17. Alekseev OM, Widgren EE, Richardson RT, O'Rand MG Association of NASP with HSP90 in mouse spermatogenic cells: stimulation of ATPase activity and transport of linker histones into nuclei. J Biol Chem 2005, 280:2904-2911.
18. Hatakeyama S, Matsumoto M, Yada M, Nakayama KI Interaction of U-box-type ubiquitin-protein ligases (E3s) with molecular chaperones. Genes Cells 2004, 9:533-548.
19. Hoffmann K, Handschumacher RE Cyclophilin-40: evidence for a dimeric complex with hsp90. Biochem J 1995, 307:5-8.
20. Pirkl F, Buchner J Functional analysis of the Hsp90-associated human peptidyl prolyl cis/trans isomerases FKBP51, FKBP52 and Cyp40. J Mol Biol 2001, 308:795-806.
21. Johnson BD, Schumacher RJ, Ross ED, Toft DO Hop modulates Hsp70/Hsp90 interactions in protein folding. J Biol Chem 1998, 273:3679-3686.
22. Ali MM, Roe SM, Vaughan CK, et al. Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature 2006, 440:1013-1017.
23. Brychzy A, Rein T, Winklhofer KF, Hartl FU, Young JC, Obermann WM Cofactor Tpr2 combines two TPR domains and a J domain to regulate the Hsp70/Hsp90 chaperone system. EMBO J 2003, 22:3613-3623.
24. Brandt GE, Blagg BS Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases. Curr Top Med Chem 2009, 9:1447-1461.
25. Mimnaugh EG, Xu W, Vos M, et al. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther 2004, 3:551-566.
26. Murphy PJ, Morishima Y, Kovacs JJ, Yao TP, Pratt WB Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone. J Biol Chem 2005, 280:33792-33799.
27. da Rocha Dias S, Friedlos F, Light Y, Springer C, Workman P, Marais R Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2005, 65:10686-10691.
28. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425:407-410.
29. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 1994, 91:8324-8328.
30. Jhaveri K, Taldone T, Modi S, Chiosis G Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 2012, 1823:742-755.
31. Banerji U, Walton M, Raynaud F, et al. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res 2005, 11:7023-7032.
32. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999, 91:1940-1949.
33. Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005, 23:4152-4161.
34. Goetz MP, Toft D, Reid J, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005, 23:1078-1087.
35. Grem JL, Morrison G, Guo XD, et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005, 23:1885-1893.
36. Nowakowski GS, McCollum AK, Ames MM, et al. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res 2006, 12:6087-6093.
37. Ramanathan RK, Egorin MJ, Eiseman JL, et al. Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin Cancer Res 2007, 13:1769-1774.
38. Solit DB, Ivy SP, Kopil C, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2007, 13:1775-1782.
39. Burris HA, Berman D, Murthy B, Jones S Tanespimycin pharmacokinetics: a randomized dose-escalation crossover phase 1 study of two formulations. Cancer Chemother Pharmacol 2011, 67:1045-1054.
40. Heath EI, Hillman DW, Vaishampayan U, et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2008, 14:7940-7946.
41. Solit DB, Osman I, Polsky D, et al. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 2008, 14:8302-8307.
42. Ronnen EA, Kondagunta GV, Ishill N, et al. A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs 2006, 24:543-546.
43. Modi S, Stopeck AT, Gordon MS, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007, 25:5410-5417.
44. Modi S, Stopeck A, Linden H, et al. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 2011, 17:5132-5139.
45. Richardson PG, Chanan-Khan AA, Alsina M, et al. Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study. Br J Haematol 2010, 150:438-445.
46. Richardson PG, Chanan-Khan AA, Lonial S, et al. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. Br J Haematol 2011, 153:729-740.
47. Pacey S, Wilson RH, Walton M, et al. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res 2011, 17:1561-1570.
48. Lancet JE, Gojo I, Burton M, et al. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 2010, 24:699-705.
49. Ramanathan RK, Egorin MJ, Erlichman C, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J Clin Oncol 2010, 28:1520-1526.
50. Kummar S, Gutierrez ME, Gardner ER, et al. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer 2010, 46:340-347.
51. Flaherty KT, Gore L, Avadhani AN, et al. First use of an oral Hsp90 inhibitor in patients with solid tumors: alvespimycin administered QOD or QD. Proc Am Soc Clin Oncol 2008, 26(suppl 15). abstr 2502.
52. Jhaveri K, Miller K, Rosen L, et al. A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors. Clin Cancer Res 2012, 18:5090-5098.
53. Wagner AJ, Morgan JA, Chugh R, et al. Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: clinical results from phase I trial. Proc Am Soc Clin Oncol 2008, 26(suppl 15). abstr 10503.
54. Siegel D, Jagannath S, Vesole DH, et al. A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. Leuk Lymphoma 2011, 52:2308-2315.
55. Riely GJ, Gettinger SN, Stoller RG, et al. Safety and activity of IPI-504 (retaspimycin hydrochloride) and docetaxel in pretreated patients (pts) with metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2011, 29. abstr 7516.
56. Oh WK, Galsky MD, Stadler WM, et al. Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology 2011, 78:626-630.
57. Sequist LV, Gettinger S, Senzer NN, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010, 28:4953-4960.
58. Demetri GD, Le Cesne A, Von Mehren M, et al. Final results from a phase III study of IPI-504 (retaspimycin hydrochloride) versus placebo in patients (pts) with gastrointestinal stromal tumors (GIST) following failure of kinase inhibitor therapies. 2010 Gastrointestinal Cancer Symposium; Orlando, FL, USA; Jan 22-24, 2010. Abstract 64.
59. Riely GJ, Gettinger SN, Stoller RG, et al. Safety and activity of IPI-504 (retaspimycin hydrochloride) and docetaxel in pretreated patients (pts) with metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2011, 29(suppl). abstr 7516.
60. Wong K, Koczywas M, Goldman JW, et al. An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2011, 29. abstr 7500.
61. Goss GD, Manegold C, Rosell R, et al. The GALAXY Trial (NCT01348126): a randomized IIB/III study of ganetespib (STA-9090) in combination with docetaxel versus docetaxel alone in subjects with stage IIIB or IV NSCLC. Proc Am Soc Clin Oncol 2012, 30. abstr TPS7613^.
62. Garon EB, Moran T, Barlesi F, et al. Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2012, 30. abstr 7543.
63. Modi S, Saura C, Henderson CA, et al. Efficacy and safety of retaspimycin hydrochloride (IPI-504) in combination with trastuzumab in patients (pts) with pretreated, locally advanced or metastatic HER2-positive breast cancer. Proc Am Soc Clin Oncol 2011, 29. abstr 590.
64. Goldman JW, Raju RN, Gordon GA, Vukovic VM, Bradley R, Rosen LS A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors. Proc Am Soc Clin Oncol 2010, 28(suppl 15). abstr 2529.
65. Cho DC, Heath EI, Cleary JM, et al. A phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: updated report. Proc Am Soc Clin Oncol 2011, 29. abstr 3051.
66. Kauh JS, Harvey RD, Owonikoko TK, et al. A phase I and pharmacokinetic study of multiple schedules of ganetespib (STA-9090), a heat shock protein 90 inhibitor, in combination with docetaxel for subjects with advanced solid tumor malignancies. Proc Am Soc Clin Oncol 2012, 30. abstr 3094.
67. Demetri GD, Heinrich MC, Chmielowski B, et al. An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST. Proc Am Soc Clin Oncol 2011, 29. abstr 10011.
68. Cercek A, Shia J, Gollub M, et al. Phase II study of ganetespib, an hsp-90 inhibitor, in patients with refractory metastatic colorectal cancer. Proc Am Soc Clin Oncol 2012, 30(suppl 4). abstr 467.
69. Samuel TA, Sessa C, Britten C, et al. AUY922, a novel HSP90 inhibitor: final results of a first-in-human study in patients with advanced solid malignancies. Proc Am Soc Clin Oncol 2010, 28(suppl 15). abstr 2528.
70. Schroder CP, Pedersen JV, Chua S, et al. Use of biomarkers and imaging to evaluate the treatment effect of AUY922, an HSP90 inhibitor, in patients with HER2+ or ER+ metastatic breast cancer. Proc Am Soc Clin Oncol 2011, 29(suppl). abstr e11024.
71. Johnson ML, Yu HA, Hart EM, et al. A phase I dose-escalation study of the HSP90 inhibitor AUY922 and erlotinib for patients with EGFR-mutant lung cancer with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs). Proc Am Soc Clin Oncol 2012, 30. abstr 3083.
72. Kong A, Rea D, Ahmed S, et al. Phase IB/II study of the HSP90 inhibitor AUY922, in combination with trastuzumab, in patients with HER2+ advanced breast cancer. Proc Am Soc Clin Oncol 2012, 30. abstr 530.
73. Mahadevan D, Rensvold DM, Kurtin SE, et al. First-in-human phase I study: results of a second-generation non-ansamycin heat shock protein 90 (HSP90) inhibitor AT13387 in refractory solid tumors. Proc Am Soc Clin Oncol 2012, 30. abstr 3028.
74. Shapiro G, Kwak EL, Dezube BJ, et al. Phase I pharmacokinetic and pharmacodynamic study of the heat shock protein 90 inhibitor AT13387 in patients with refractory solid tumors. Proc Am Soc Clin Oncol 2010, 28(suppl 15). abstr 3069.
75. Do KT, Speranza G, Chen AP, et al. Phase l study assessing a two-consecutive-day (QD × 2) dosing schedule of the HSP90 inhibitor, AT13387, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2012, 30. abstr 3087.
76. Daruka Mahadevan, Diane M Rensvold, Sandra E Kurtin, et al. First-in-human phase I study: results of a second-generation non-ansamycin heat shock protein 90 (HSP90) inhibitor AT13387 in refractory solid tumors. Proc Am Soc Clin Oncol 2012, 30(suppl). abstr 3028.
77. Elfiky A, Saif MW, Beeram M, et al. BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: phase I experience. Proc Am Soc Clin Oncol 2008, 26(suppl 15). abstr 2503.
78. Dickson MA, Okuno SH, Keohan ML, et al. Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. Ann Oncol 2013, 24:252-257.
79. Modi S, Ismail-Khan R, Munster P, et al. Phase 1 dose-escalation study of the heat shock protein 90 inhibitor BIIB021 with trastuzumab in HER2+ metastatic breast cancer. CTRC-AACR San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 8-12, 2010. Abstract P3-14-02.
80. Yu MK, Samlowski WE, Baichwal V, et al. MPC-3100, a fully synthetic, orally bioavailable Hsp90 inhibitor, in cancer patients. Proc Am Soc Clin Oncol 2010, 28. abstr e13112.
81. Isambert N, Hollebecque A, Berge Y, et al. A phase I study of Debio 0932, an oral HSP90 inhibitor, in patients with solid tumors. Proc Am Soc Clin Oncol 2012, 30. abstr 3026.
82. Rajan A, Kelly RJ, Trepel JB, et al. A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res 2011, 17:6831-6839.
83. Kabakov AE, Kudryavtsev VA, Gabai VL Hsp90 inhibitors as promising agents for radiotherapy. J Mol Med (Berl) 2010, 88:241-247.
84. Gallegos-Ruiz MI, Floor K, Roepman P, et al. Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS One 2008, 3:e0001722.
85. Pick E, Kluger Y, Giltnane JM, et al. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 2007, 67:2932-2937.
86. Jhaveri KL, Iyengar NM, Corben A, et al. Biomarkers that predict sensitivity to heat shock protein 90 inhibitors (HSP90i). Proc Am Soc Clin Oncol 2012, 30. abstr 10618.
87. Powers MV, Clarke PA, Workman P Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 2008, 14:250-262.
88. Van de Ven SM, Elias SG, Chan CT, et al. Optical imaging with her2-targeted affibody molecules can monitor hsp90 treatment response in a breast cancer xenograft mouse model. Clin Cancer Res 2012, 18:1073-1081.
89. Clarke PA, Hostein I, Banerji U, et al. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene 2000, 19:4125-4133.
90. Chung YL, Troy H, Banerji U, et al. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino, 17-demethoxygeldanamycin (17AAG) in human colon cancer models. J Natl Cancer Inst 2003, 95:1624-1633.
91. Lu X, Xiao L, Wang L, Ruden DM Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs. Biochem Pharmacol 2012, 83:995-1004.